European Commission - Directorate General for Energy
European Commission - Directorate General for Energy
01/10/2025 | Press release | Distributed by Public on 01/10/2025 03:07
Revised versions of the PAR templates and the form to apply for designation as NB as well as their annexes are available in the Notified Bodies section
This page provides a range of documents to assist stakeholders in applying:
Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 (IVDR) on in vitro diagnostic medical devices.
The majority of documents on this page are endorsed by the Medical Device Coordination Group (MDCG) in accordance with Article 105 of the MDR and Article 99 of the IVDR.
They are drafted in collaboration with interested parties represented in the various groups and denominated by the following format: "MDCG Year-Number-revision".
The documents on this page are not legally binding. They present a common understanding of how the MDR and IVDR should be applied in practice aiming at an effective and harmonised implementation of the legislation.
Annex XVI products
Borderline and Classification
Class I Devices
| MDCG 2020-2 rev.1 | Class I transitional provisions under Article 120 (3 and 4) - (MDR) | March 2020 |
| MDCG 2019-15 rev.1 | Guidance notes for manufacturers of class I medical devices | December 2019 |
Clinical investigation and evaluation
| MDCG 2024-15 | Guidance on the publication of the clinical investigation reports and their summaries in the absence of EUDAMED | November 2024 |
| MDCG 2024-10 | Clinical evaluation of orphan medical devices | June 2024 |
|
Guidance on the Investigator's Brochure content Appendix A of the MDCG 2024-5 |
April2024 April2024 |
|
|
Guidance on content of the Clinical Investigation Plan for clinical investigations of medical devices Clinical Investigation Plan Synopsis Template |
March 2024 March 2024 |
|
| MDCG 2023-7 | Guidance on exemptions from the requirement to perform clinical investigations pursuant to Article 61(4)-(6) MDR and on sufficient levels of access' to data needed to justify claims of equivalence | December 2023 |
| 2023/C 163/06 | Commission Guidance on the content and structure of the summary of the clinical investigation report | May 2023 |
| MDCG 2021-28 | Substantial modification of clinical investigation under Medical Device Regulation | December 2021 |
| MDCG 2021-20 | Instructions for generating CIV-ID for MDR Clinical Investigations | July 2021 |
| MDCG 2021-8 | Clinical investigation application/notification documents | May 2021 |
| MDCG 2021-6 - rev.1 | Regulation (EU) 2017/745 - Questions & Answers regarding clinical investigation | December 2023 |
| MDCG 2020-13 - Word version | Clinical evaluation assessment report template | July 2020 |
|
Guidance on safety reporting in clinical investigations Appendix: Clinical investigation summary safety report form |
October 2022 October 2022 |
|
| MDCG 2020-8 | Guidance on PMCF evaluation report template | April 2020 |
| MDCG 2020-7 | Guidance on PMCF plan template | April 2020 |
| MDCG 2020-6 |
Guidance on sufficient clinical evidence for legacy devices Background note on the relationship between MDCG 2020-6 and MEDDEV 2.7/1 rev.4 on clinical evaluation |
April 2020 |
| MDCG 2020-5 | Guidance on clinical evaluation - Equivalence | April 2020 |
| MDCG 2019-9 - rev.1 | Summary of safety and clinical performance | March 2022 |
COVID-19
Custom-Made Devices
| MDCG 2021-3 | Questions and Answers on Custom-Made Devices | March 2021 |
EUDAMED
| Gradual roll out of EUDAMED | Q&A on practical aspects related to the implementation of the gradual roll-out of Eudamed pursuant to the MDR and IVDR, as amended by Regulation (EU) 2024/1860 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, the obligation to inform in case of interruption or discontinuation of supply, and transitional provisions for certain in vitro diagnostic medical devices1 | November 2024 |
| MDCG 2022-12 | Guidance on harmonised administrative practices and alternative technical solutions until Eudamed is fully functional (for Regulation (EU) 2017/746 on in vitro diagnostic medical devices) | July 2022 |
| MDCG 2021-13 rev.1 | Questions and answers on obligations and related rules for the registration in EUDAMED of actors other than manufacturers, authorised representatives and importers subject to the obligations of Article 31 MDR and Article 28 IVDR | July 2021 |
| MDCG 2021-1 rev.1 | Guidance on harmonised administrative practices and alternative technical solutions until EUDAMED is fully functional | May 2021 |
| MDCG 2020-15 | MDCG Position Paper on the use of the EUDAMED actor registration module and of the Single Registration Number (SRN) in the Member States | August 2020 |
| MDCG 2019-5 | Registration of legacy devices in EUDAMED | April 2019 |
| MDCG 2019-4 | Timelines for registration of device data elements in EUDAMED | April 2019 |
European Medical Device Nomenclature (EMDN)
Implant cards
| MDCG 2021-11 | Guidance on Implant Card - Device types | May 2021 |
| MDCG 2019-8 v2 | Guidance document implant card on the application of Article 18 Regulation (EU) 2017/745 on medical devices | March 2020 |
In-house devices
| MDCG 2023-1 | Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746 | January 2023 |
Authorised Representatives, Importers, Distributors
| MDCG 2021-27 - rev.1 | Questions and Answers on Articles 13 & 14 of Regulation (EU) 2017/745 and Regulation (EU) 2017/746 | December 2023 |
| MDCG 2022-16 | Guidance on Authorised Representatives Regulation (EU) 2017/745 and Regulation (EU) 2017/746 | October 2022 |
| MDCG 2021-26 | Q&A on repackaging & relabelling activities under Article 16 of Regulation (EU) 2017/745 and Regulation (EU) 2017/746 | October 2021 |
Article 10a - interruption or discontinuation of supply
| Q&A rev.1 | Q&A Obligation to inform in case of interruption or discontinuation of supply | December 2024 |
| MDCG 2024-16 | Manufacturer Information Form on Interruption or Discontinuation of Supply of certain medical devices and certain in vitro diagnostic medical devices | December 2024 |
| MDCG 2024-16 Annex | Device Identification table | December 2024 |
In Vitro Diagnostic medical devices (IVD)
| MDCG 2024-11 | Guidance on qualification of in vitro diagnostic medical devices | October 2024 |
|
Safety reporting in performance studies of in vitro diagnostic medical devices under Regulation (EU) 2017/746 Appendix - Performance Study Summary Safety Reporting Form |
April 2024 | |
| MDCG 2022-9 rev.1 | Summary of safety and performance template | April 2024 |
| MDCG 2020-16 rev.3 | Guidance on Classification Rules for in vitro Diagnostic Medical Devices under Regulation (EU) 2017/746 | July 2024 |
| MDCG 2022-20 | Substantial modification of performance study under Regulation (EU) 2017/746 | December 2022 |
| MDCG 2022-19 | Performance study application/notification documents under Regulation (EU) 2017/746 | December 2022 |
| MDCG 2022-15 | Guidance on appropriate surveillance regarding the transitional provisions under Article 110 of the IVDR with regard to devices covered by certificates according to the IVDD | September 2022 |
| MDCG 2021-22 rev.1 | Clarification on "first certification for that type of device" and corresponding procedures to be followed by notified bodies, in context of the consultation of the expert panel referred to in Article 48(6) of Regulation (EU) 2017/746 | September 2022 |
| MDCG 2022-10 | Q&A on the interface between Regulation (EU) 536/2014 on clinical trials for medicinal products for human use (CTR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) | May 2022 |
| MDCG 2022-8 | Regulation (EU) 2017/746 - application of IVDR requirements to 'legacy devices' and to devices placed on the market prior to 26 May 2022 in accordance with Directive 98/79/EC | May 2022 |
| MDCG 2022-6 | Guidance on significant changes regarding the transitional provision under Article 110(3) of the IVDR | May 2022 |
| MDCG 2022-3 rev.1 | Verification of manufactured class D IVDs by notified bodies | December 2024 |
| MDCG 2022-2 | Guidance on general principles of clinical evidence for In Vitro Diagnostic medical devices (IVDs) | January 2022 |
| MDCG 2021-4 rev.1 | Application of transitional provisions for certification of class D in vitro diagnostic medical devices according to Regulation (EU) 2017/746 | September 2024 |
New technologies
| MDCG 2023-4 | Medical Device Software (MDSW) - Hardware combinations Guidance on MDSW intended to work in combination with hardware or hardware components | October 2023 |
| Infographic | Is your software a Medical Device? | March 2021 |
| MDCG 2020-1 | Guidance on clinical evaluation (MDR) / Performance evaluation (IVDR) of medical device software | March 2020 |
| MDCG 2019-16 rev.1 | Guidance on cybersecurity for medical devices | December 2019 |
| MDCG 2019-11 | Qualification and classification of software - Regulation (EU) 2017/745 and Regulation (EU) 2017/746 | October 2019 |
Notified bodies
| MDCG 2024-6 | Preliminary re-assessment review (PRAR) form template (MDR) | May 2024 |
|
Preliminary assessment review (PAR) form template (MDR) Annex to Application Form & PAR Template MDR (List of documents) |
January 2025 | |
|
Preliminary assessment review (PAR) form template (IVDR) Annex to Application Form & PAR Template IVDR (List of documents) |
May 2024 | |
| MDCG 2024-9 | Preliminary re-assessment review (PRAR) form template (IVDR) | May 2024 |
| MDCG 2020-3 rev.1 |
Guidance on significant changes regarding the transitional provision under Article 120 of the MDR with regard to devices covered by certificates according to MDD or AIMDD Note to the reader: Due to technical issues, please disregard the document displayed from 7 September 2023 until 8 September 2023. |
September 2023 |
|
MDCG 2023-2 MDCG 2023-2 MDR form MDCG 2023-2 IVDR form |
List of Standard Fees | January 2023 |
| MDCG 2022-4 rev.2 | Guidance on appropriate surveillance regarding the transitional provisions under Article 120 of the MDR with regard to devices covered by certificates according to the MDD or the AIMDD | May 2024 |
| MDCG 2022-17 | MDCG position paper on "hybrid audits" | December 2022 |
| MDCG 2019-6 rev.4 | Questions and answers: Requirements relating to notified bodies | October 2022 |
| MDCG 2022-13 rev.1 | Designation, re-assessment and notification of conformity assessment bodies and notified bodies | June 2024 |
|
Corrective and preventive action (CAPA) plan assessment: guidance and templates for conformity assessment bodies, notified bodies, designating authorities, and joint assessment teams Annex I: Template CAPA plan and assessment thereon Annex II: Template JAT review of the CAPA and the DA's opinion |
October 2024 | |
| MDCG 2021-23 | Guidance for notified bodies, distributors and importers on certification activities in accordance with Article 16(4) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746 | August 2021 |
| MDCG 2021-18 | Applied-for scope of designation and notification of a conformity assessment body - Regulation (EU) 2017/746 (IVDR) | July 2021 |
| MDCG 2021-17 | Applied-for scope of designation and notification of a conformity assessment body - Regulation (EU) 2017/745 (MDR) | January 2025 |
|
Application form to be submitted by a conformity assessment body when applying for designation as notified body under the in vitro diagnostic devices regulation (IVDR) Annex to Application Form & PAR Template IVDR (List of documents) |
January 2025 | |
|
Application form to be submitted by a conformity assessment body when applying for designation as notified body under the medical devices regulation (MDR) Annex to Application Form & PAR Template MDR (List of documents) |
July 2021 | |
| MDCG 2021-14 | Explanatory note on IVDR codes | July 2021 |
| MDCG 2020-17 |
Questions and Answers related to MDCG 2020-4: "Guidance on temporary extraordinary measures related to medical device notified body audits during COVID-19 quarantine orders and travel restrictions" |
December 2020 |
| MDCG 2020-14 | Guidance for notified bodies on the use of MDSAP audit reports in the context of surveillance audits carried out under the Medical Devices Regulation (MDR)/In Vitro Diagnostic medical devices Regulation (IVDR) | August 2020 |
| MDCG 2020-12 | Guidance on transitional provisions for consultations of authorities on devices incorporating a substance which may be considered a medicinal product and which has action ancillary to that of the device, as well as on devices manufactured using TSE susceptible animal tissues | June 2020 |
| MDCG 2020-11 | Guidance on the renewal of designation and monitoring of notified bodies under Directives 90/385/EEC and 93/42/EEC to be performed in accordance with Commission Implementing Regulation (EU) 2020/666 amending Commission Implementing Regulation (EU) 920/2013 | May 2020 |
| MDCG 2020-4 | Guidance on temporary extraordinary measures related to medical device notified body audits during COVID-19 quarantine orders and travel restrictions | April 2020 |
| MDCG 2019-14 | Explanatory note on MDR codes | December 2019 |
| MDCG 2019-13 rev.1 | Guidance on sampling of devices for the assessment of the technical documentation | December 2024 |
| MDCG 2019-12 | Designating authority's final assessment form: Key information (EN) | October 2019 |
| MDCG 2019-10 rev.1 | Application of transitional provisions concerning validity of certificates issued in accordance to the directives | October 2019 |
| MDCG 2018-8 | Guidance on content of the certificates, voluntary certificate transfers | November 2018 |
| NBOG BPG 2017-2 | Best practice guidance on the information required for personnel involved in conformity assessment | February 2018 |
| NBOG F 2017-8 | Review of qualification for the authorisation of personnel (IVDR) | February 2018 |
| NBOG F 2017-7 | Review of qualification for the authorisation of personnel (MDR) | February 2018 |
Person responsible for regulatory compliance (PRRC)
| MDCG 2019-7 - rev.1 | Guidance on article 15 of the medical device regulation (MDR) and in vitro diagnostic device regulation (IVDR) on a 'person responsible for regulatory compliance' (PRRC) | December 2023 |
Post-Market Surveillance and Vigilance (PMSV)
| MDCG 2024-1 | Device Specific Vigilance Guidance (DSVG) Template | January 2024 |
| MDCG 2024-1-1 | DSVG 01 on Cardiac ablation | January 2024 |
| MDCG 2024-1-2 | DSVG 02 on Coronary stents | January 2024 |
| MDCG 2024-1-3 | DSVG 03 on Cardiac implantable electronic devices (CIEDs) | January 2024 |
| MDCG 2024-1-4 | DSVG 04 on Breast implants | January 2024 |
| MDCG 2024-1-5 | DSVG 05 on Urogynaecological Surgical Mesh Implants used for Pelvic Organ Prolapse repair and Stress Urinary Incontinence | June 2024 |
| MDCG 2023-3 rev.2 | Questions and Answers on vigilance terms and concepts as outlined in the Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 | January 2025 |
| MDCG 2022-21 | Guidance on Periodic Safety Update Report (PSUR) according to Regulation (EU) 2017/745 | December 2022 |
Standards
Unique Device Identifier (UDI)
| MDCG 2024-14 | Guidance on the implementation of the Master UDI-DI solution for contact lenses | November 2024 |
| MDCG 2022-7 | Q&A on the Unique Device Identification system under Regulation (EU) 2017/745 and Regulation (EU) | May 2022 |
| MDCG 2021-19 | Guidance note integration of the UDI within an organisation's quality management system | July 2021 |
| MDCG 2021-10 | The status of Appendixes E-I of IMDRF N48 under the EU regulatory framework for medical devices | June 2021 |
| MDCG 2021-09 | MDCG Position Paper on the Implementation of UDI requirements for contact lenses, spectacle frames, spectacle lenses & ready readers | May 2021 |
| MDCG 2018-1 rev.4 | Guidance on basic UDI-DI and changes to UDI-DI | April 2021 |
| MDCG 2020-18 | MDCG Position Paper on UDI assignment for Spectacle lenses & Ready readers | December 2020 |
| MDCG 2019-2 | Guidance on application of UDI rules to device-part of products referred to in article 1(8), 1(9) and 1(10) of Regulation 745/2017 | February 2019 |
| MDCG 2019-1 | MDCG guiding principles for issuing entities rules on basic UDI-DI | January 2019 |
| MDCG 2018-7 | Provisional considerations regarding language issues associated with the UDI database | October 2018 |
| MDCG 2018-6 | Clarifications of UDI related responsibilities in relation to article 16 | October 2018 |
| MDCG 2018-5 | UDI assignment to medical device software | October 2018 |
| MDCG 2018-4 | Definitions/descriptions and formats of the UDI core elements for systems or procedure packs | October 2018 |
| MDCG 2018-3 rev.1 | Guidance on UDI for systems and procedure packs | June 2020 |
Other topics
| Q&A | Q&A on practical aspects related to the implementation of the extended transitional period provided for in the IVDR, as amended by Regulation (EU) 2024/1860 | July 2024 |
| MDCG 2022-11 - rev.1 | MDCG Position Paper: Notice to manufacturers to ensure timely compliance with MDR and IVDR requirements | November 2023 |
| Q&A rev.2 | Q&A on practical aspects related to the implementation of Regulation (EU) 2023/607 - Extension of the MDR transitional period and removal of the "sell off" periods | July 2024 |
| MDCG 2022-18 ADD.1 | MDCG Position Paper on the application of Article 97 MDR to legacy devices for which the MDD or AIMDD certificate expires before the issuance of a MDR certificate - Addendum 1 | June 2023 |
| MDCG 2022-18 | MDCG Position Paper on the application of Article 97 MDR to legacy devices for which the MDD or AIMDD certificate expires before the issuance of a MDR certificate | December 2022 |
| MDCG 2022-14 | Transition to the MDR and IVDR - Notified body capacity and availability of medical devices and IVDs | August 2022 |
| MDCG 2021-25 rev.1 | Application of MDR requirements to "legacy devices" and to devices placed on the market prior to 26 May 2021 in accordance with Directives 90/385/EEC or 93/42/EEC | October 2024 |
| MDCG 2019-3 rev.1 | Clinical evaluation consultation procedure exemptions Interpretation of article 54(2)b | April 2020 |
Other guidance documents
| MDR/IVDR Language requirements | Overview of language requirements for manufacturers of medical devices for the information and instructions that accompany a device in a specific country | January 2024 |
| European Medicines Agency (EMA) Guidance | Questions & Answers for applicants, marketing authorisation holders of medicinal products and notified bodies with respect to the implementation of the Medical Devices and In Vitro Diagnostic Medical Devices Regulations ((EU) 2017/745 and (EU) 2017/746) | June 2021 |
| SCHEER guidelines |
Update on the guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties |
June 2024 |
| CAMD FAQ | CAMD MDR/IVDR Transition Subgroup: FAQ - MDR Transitional provisions | January 2018 |